| |
| Trade Name | LIPOSORBER LA-15 System |
| Classification Name | apheresis for focal glomerulosclerosis in adult and pediatric patients |
| Generic Name | apheresis for focal glomerulosclerosis in adult and pediatric patients |
| Applicant |
| Kaneka Pharma America, LLC |
| 546 fifth ave., 21st floor |
| new york, NY 10036 |
|
| HDE Number | H170002 |
| Date Received | 06/16/2017 |
| Decision Date | 03/20/2018 |
| Product Code | |
| Docket Number | 18M-1215 |
| Notice Date | 04/11/2018 |
| Advisory Committee |
Gastroenterology |
| Supplement Type | hde original |
| Expedited Review Granted? | No |
| Combination Product | No |
Approval Order Statement Approval for the liposorber® la-15 system to expand the indication to include adult patients with nephrotic syndrome. The liposorber® la-15 is indicated for use in the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, are unsuccessful or not well tolerated and the patient has a gfr >= 60 ml/min/1. 73m2 or the patient is post renal transplantation. |
| Approval Order | Approval Order |
| Summary | Summary of Safety And Probable Benefit |
| Labeling | Labeling Labeling Part 2 |
| Post-Approval Study | Show Report Schedule and Study Progress |
| Supplements: |
S001 S002 S003 S004 S005 S006 S007 S008 S009 S010 S011 S012 S013 S014 S015 S016 S018 |